Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EIGR
- Price
- -
- Stock movement up
- +0.33 (18.84%)
- Company name
- Eiger Biopharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.03M
- Ent value
- 30.88M
- Price/Sales
- 0.19
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -15.03%
- 1 year return
- -92.45%
- 3 year return
- -79.89%
- 5 year return
- -65.93%
- 10 year return
- -53.29%
Last updated: 2024-12-17
DIVIDENDS
EIGR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.19 |
| Price to Book | - |
| EV to Sales | 1.96 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.48M |
| EPS (TTM) | -50.76 |
| FCF per share (TTM) | -50.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 15.77M |
| Gross profit (TTM) | 15.13M |
| Operating income (TTM) | -71.79M |
| Net income (TTM) | -74.96M |
| EPS (TTM) | -50.76 |
| EPS (1y forward) | -3.60 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.92% |
| Operating margin (TTM) | -455.12% |
| Profit margin (TTM) | -475.26% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 25.44M |
| Net receivables | 1.68M |
| Total current assets | 37.84M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.80M |
| Total assets | 38.83M |
| Accounts payable | 2.12M |
| Short/Current long term debt | 41.20M |
| Total current liabilities | 53.28M |
| Total liabilities | 53.28M |
| Shareholder's equity | -14.46M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -74.55M |
| Capital expenditures (TTM) | 234.00K |
| Free cash flow (TTM) | -74.78M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -193.07% |
| Return on Invested Capital | -280.29% |
| Cash Return on Invested Capital | -279.61% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| EIGR | S&P500 | |
| Current price drop from All-time high | -99.98% | -0.99% |
| Highest price drop | -99.99% | -56.47% |
| Date of highest drop | 2 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -88.57% | -11.07% |
| Avg time to new high | 103 days | 12 days |
| Max time to new high | 2282 days | 1805 days |
COMPANY DETAILS
Marketcap
3.03M
Marketcap category
Small-cap
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Employees
56
Website
Investor relations
-
SEC filings
CEO
David A. Cory
Country
USA
City
Palo Alto
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner